Aardvark Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary

Aardvark Therapeutics

12/08/2026 15:41

Aardvark Therapeutics, Inc. AARD.OQ reported a quarterly adjusted loss of 66 cents​​ per share for the quarter ended June 30, identical to the same quarter last year.  The mean expectation of twelve analysts for the quarter was for a loss of 87 cents per share. Wall Street expected results to range from $-1.08 to -45 cents per share.
Reported revenue was zero​; analysts expected zero. 
Aardvark Therapeutics, Inc.'s reported EPS for the quarter was a loss of 66 cents​.
The company reported a quarterly loss of $14.39 million.
Aardvark Therapeutics, Inc. shares had risen by 24.8% this quarter and lost 45.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 0.6% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 4 "hold" and 2 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Aardvark Therapeutics, Inc. is $7.00, about 2.7% below its last closing price of $7.19
This summary was machine generated from LSEG data August 12 at 02:41 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.87
-0.66
Beat
Mar. 31 2026 
-0.88
-0.99
Missed
Dec. 31 2025 
-0.83
-0.81
Beat
Sep. 30 2025 
-0.80
-0.75
Beat